Investing

Goldman Sachs Has 5 Stocks Under $10 Rated Buy With 125% to 400% Upside Potential

Angi also operates Handy, a platform for household services, primarily cleaning and repair services; Angi Roofing, which provides roof replacement and repair services; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder and Instapro names.

Goldman Sachs has a $12 price target for Angi stock, while the consensus target is $11.59. The shares closed trading on Friday at $4.73. Hitting the Goldman Sachs target would be about a 128% gain.

Array Technologies

This company is still sometimes confused with a biotech with a similar name that Pfizer bought in 2019. Array Technologies Inc. (NASDAQ: ARRY) provides solar tracking solutions and services for utility-scale projects. Its products include DuraTrack HZ v3, a single-axis solar tracking system, and SmarTrack, a machine learning software that automatically adjusts module angles in response to weather and site conditions.

This stock had a red-hot initial public offering in 2020. Shares charged out of the gate, as the first trade was 34% above where the upsized IPO was priced. A total of 47.5 million shares were sold in the offering, as the maker of ground-mounting systems used in solar energy projects sold 7 million shares to raise $154 million and a selling shareholder sold 40.5 million shares.

Since then, Array Technologies stock has crashed and is offering investors an incredible entry point.

The Goldman Sachs target price is $21, and the consensus target for Array Technologies stock is $21.80. Shares traded on Friday at $7.02 down 5%. Hitting the Goldman Sachs target would be a 148% gain or so.

Kinnate Biopharma

If clinical data goes the way the analysts expect, this stock could be an incredible home run. Kinnate Biopharma Inc. (NASDAQ: KNTE) is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.

The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.

The company recently announced that the first patient has commenced treatment in its Phase 1 KN-4802 clinical trial evaluating its lead fibroblast growth factor receptor (FGFR) product candidate, KIN-3248. This is a next-generation pan-FGFR inhibitor being developed for the treatment of intrahepatic cholangiocarcinoma and urothelial carcinoma, as well as other solid tumors.

The $44 Goldman Sachs price objective is higher than the also incredible $41.50 consensus target. The shares closed trading at $8.26 on Friday. Hitting the Goldman Sachs target would be a moonshot 415% gain.

Vivint Smart Home

This off-the-radar company has been growing quickly, as home security has become a priority for many. Vivint Smart Home Inc. (NYSE: VVNT) engages in the sale, installation, servicing and monitoring of smart home and security systems, primarily in the United States and Canada.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.